An FDA advisory committee meeting ends in advice, not a decision. The outside experts weigh the evidence, then answer questions the agency has put in writing. The people in the room do not approve anything themselves, and many approvals skip the panels entirely. The distance showed in 2021, when the agency approved an Alzheimer’s treatment against a nearly unanimous negative committee vote (Health Affairs, 2022).
The fastest way to see the gap is a fresh approval on the calendar. This report on the agency’s oveporexton decision for narcolepsy follows the decision side of that line. Ongoing coverage of regulatory news sits on the site’s health-news hub. Committees advise across drugs, devices and foods.
Who sits on an FDA advisory committee?
Technically qualified experts, by the agency’s own standard. FDA requires scientific members who are experts in fields from clinical medicine to biostatistics (FDA, 2018). Public seats go to Consumer Representatives and Patient Representatives. Industry Representatives sit as non-voting members (FDA, 2018).
Turnover is part of the design. Nomination calls and vacancy notices run through the Federal Register (FDA, 2018). The notices spell out the field of expertise each opening requires. We covered a connected angle in FDA Approved Hepcludex, Closing the US Gap in Hepatitis D Treatment.
The consumer seat is not decorative. A Consumer Representative must be able to analyze scientific data and evaluate the safety and efficacy of products under review (FDA, 2018). The industry seat carries no vote. Its occupant speaks for the regulated sector as a whole, not for one firm (FDA, 2018).
What actually happens at the meeting?
A scripted public process. The mechanics are fixed, and each one is documented on the agency’s meeting page (FDA, 2024).
- Notice goes into the Federal Register at least 15 calendar days before the meeting date (41 CFR 102-3.150).
- Background materials are posted no later than two business days before the session.
- Registered speakers can address the committee during the Open Public Hearing.
- Transcripts generally appear within 90 days of the session.
- Some meetings are webcast at no cost to viewers.
The agency writes the voting questions, and the wording matters. The Health Affairs review found wide variation in the wording of key voting questions (Daval et al., 2022). The Open Public Hearing is where patient groups and drugmakers get their turn on the record. Everything lands in public, which is the point of staging the debate outside the agency.
Webcasts are free when a meeting offers one (FDA, 2024). Anyone can watch the argument as it happens, including the moments the committee splits. The camera changes no votes, but it preserves them. The point is access, not spectacle.
What does the vote actually decide?
Nothing by itself. A committee vote is a recommendation the agency can follow or decline. The 2022 review in Health Affairs found approvals running against a negative committee vote about once a year (Daval et al., 2022). The documented example is aducanumab, an Alzheimer’s treatment approved in 2021 despite a nearly unanimous negative vote (Daval et al., 2022).
The vote still matters, because it moves the disagreement into the record. Reviewers and the public can read who doubted the evidence, and on which exact question. The same review called for clear criteria on which drugs face outside scrutiny (Daval et al., 2022). A split vote also shows where a future label’s weak points sit.
Conclusion: how to read the next committee vote
Read the vote as a signal, and read the approval letter as the act that changes access. Committee members bring outside expertise, but the 2010 through 2021 record shows the agency treats their advice as input (Daval et al., 2022). The panels shape the argument even when they lose it, and the transcript stays public either way (FDA, 2024). Follow the next session with that caution in mind: this is information, not medical or insurance advice.
